Colchicine for Stroke Prevention (CHANCE-3 Trial)
๐ Study Type: Randomized, placebo-controlled trial
๐ฅ Setting: 244 hospitals in China
๐ฅ Participants: 8,343 patients (age โฅ40) with minor/moderate ischemic stroke or TIA & hs-CRP โฅ2 mg/L
Intervention vs. Control
๐ Colchicine Group (n=4,176)
โข 0.5 mg twice daily (Days 1-3) โ 0.5 mg daily (Days 4-90)
๐ Placebo Group (n=4,167)
โข Identical dosing schedule
Key Outcomes (90 Days)
โ
Primary Efficacy: Any stroke
โข Colchicine: 6.3% (264 patients)
โข Placebo: 6.5% (270 patients)
๐ No significant difference (HR 0.98, P=0.79)
โ ๏ธ Primary Safety: Serious adverse events
โข Colchicine: 2.2%
โข Placebo: 2.1%
๐น No significant difference (P=0.83)
Conclusion
๐ Colchicine did not reduce stroke risk within 90 days in high-risk patients.
๐ Safety profile was similar to placebo.